MAM
MLYS icon

Meeder Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Meeder Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,338
Closed -$16.5K – 992
2024
Q4 		$16.5K Buy
+1,338
New +$17.5K ﹤0.01% 584

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Meeder Asset Management's MLYS Position: Q1 2025 in Review

Meeder Asset Management sold out of Mineralys Therapeutics (MLYS) in Q1 2025, closing a stake of 1,338 shares — an estimated $16.5K sold.

Meeder Asset Management first reported a position in MLYS in Q4 2024 and held it in 1 quarter. The position peaked at $16.5K in Q4 2024. 149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • Meeder Asset Management reported no remaining Mineralys Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Meeder Asset Management sold 1,338 Mineralys Therapeutics shares in Q1 2025, an estimated $16.5K.
  • Meeder Asset Management first reported a position in Mineralys Therapeutics in Q4 2024 and held it in 1 quarter.
  • Meeder Asset Management's Mineralys Therapeutics position peaked at $16.5K in Q4 2024.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on Meeder Asset Management's 13F filing for Q1 2025, filed 7 May 2025.